10.14
price down icon0.10%   -0.010
after-market Handel nachbörslich: 10.14
loading

Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten

pulisher
Oct 27, 2024

Cell therapy developer Artiva refiles for a $100M IPO - MSN

Oct 27, 2024
pulisher
Oct 23, 2024

Artiva Biotherapeutics appoints new board member By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - ForexTV.com

Oct 23, 2024
pulisher
Oct 22, 2024

Artiva Biotherapeutics, Inc. Appoints Alison Moore as an Independent Member of Its Board of Directors - Marketscreener.com

Oct 22, 2024
pulisher
Oct 22, 2024

Artiva Biotherapeutics appoints new board member - Investing.com

Oct 22, 2024
pulisher
Oct 15, 2024

Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online

Oct 15, 2024
pulisher
Oct 15, 2024

Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price Down 5.4%Time to Sell? - MarketBeat

Oct 15, 2024
pulisher
Sep 28, 2024

Wall Street SWOT: Artiva Biotherapeutics stockNK cell pioneer targets autoimmune market By Investing.com - Investing.com South Africa

Sep 28, 2024
pulisher
Sep 23, 2024

The Attractiveness of Investing In Artiva Biotherapeutics Inc (ARTV) is Growing - Knox Daily

Sep 23, 2024
pulisher
Sep 21, 2024

Artiva Biotherapeutics (NASDAQ:ARTV) Trading 6.2% Higher - MarketBeat

Sep 21, 2024
pulisher
Sep 10, 2024

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference - GlobeNewswire

Sep 10, 2024
pulisher
Aug 29, 2024

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Aug 29, 2024
pulisher
Aug 29, 2024

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment - AOL

Aug 29, 2024
pulisher
Aug 21, 2024

Artiva Biotherapeutics, Inc.’s (NASDAQ:ARTV) Quiet Period Will End on August 28th - Defense World

Aug 21, 2024
pulisher
Aug 21, 2024

Artiva Biotherapeutics, Inc.'s Quiet Period Set To Expire on August 28th (NASDAQ:ARTV) - MarketBeat

Aug 21, 2024
pulisher
Aug 16, 2024

Brokers Issue Forecasts for Artiva Biotherapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ARTV) - MarketBeat

Aug 16, 2024
pulisher
Aug 15, 2024

Analysts Set Expectations for Artiva Biotherapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:ARTV) - Defense World

Aug 15, 2024
pulisher
Aug 13, 2024

Artiva Biotherapeutics (NASDAQ:ARTV) Stock Quotes, Forecast and News Summary - Benzinga

Aug 13, 2024
pulisher
Aug 13, 2024

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch - Benzinga

Aug 13, 2024
pulisher
Aug 13, 2024

Artiva Biotherapeutics (NASDAQ:ARTV) Receives New Coverage from Analysts at TD Cowen - Defense World

Aug 13, 2024
pulisher
Aug 13, 2024

Needham & Company LLC Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World

Aug 13, 2024
pulisher
Aug 13, 2024

Wedbush Initiates Coverage on Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World

Aug 13, 2024
pulisher
Aug 13, 2024

Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat

Aug 13, 2024
pulisher
Aug 13, 2024

Artiva Biotherapeutics (NASDAQ:ARTV) Coverage Initiated by Analysts at Cantor Fitzgerald - Defense World

Aug 13, 2024
pulisher
Aug 12, 2024

Non-Hodgkin Lymphoma Drugs Pipeline 2024 | Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc - Barchart

Aug 12, 2024
pulisher
Aug 06, 2024

July IPOs to Watch in Tech, Biotech, Food Security and Transportation - Investorideas.com newswire

Aug 06, 2024
pulisher
Jul 28, 2024

Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares - 24/7 Wall St.

Jul 28, 2024
pulisher
Jul 28, 2024

Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal - Seeking Alpha

Jul 28, 2024
pulisher
Jul 23, 2024

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Yong-Jun Huh Buys 2,083,332 Shares - Defense World

Jul 23, 2024
pulisher
Jul 23, 2024

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Major Shareholder Global Strategic Fund I. Venbio Purchases 416,666 Shares - Defense World

Jul 23, 2024
pulisher
Jul 23, 2024

VenBio fund acquires $5m in Artiva Biotherapeutics stock By Investing.com - Investing.com Australia

Jul 23, 2024
pulisher
Jul 22, 2024

VenBio fund acquires $5m in Artiva Biotherapeutics stock - Investing.com India

Jul 22, 2024
pulisher
Jul 22, 2024

Artiva Biotherapeutics sees major stock purchases by GC Corp entities - Investing.com South Africa

Jul 22, 2024
pulisher
Jul 22, 2024

Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO By Investing.com - Investing.com South Africa

Jul 22, 2024
pulisher
Jul 22, 2024

Artiva Biotherapeutics director Yong-Jun Huh buys $25m in IPO - Investing.com India

Jul 22, 2024
pulisher
Jul 22, 2024

Artiva: Natural Killer Cell Biotech With First Half Of 2025 Lupus Treatment Data - Seeking Alpha

Jul 22, 2024
pulisher
Jul 21, 2024

Artiva’s IPO Reels In $167M to Bring NK Cell Therapy to Autoimmune Diseases - MedCity News

Jul 21, 2024
pulisher
Jul 20, 2024

Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Jul 20, 2024
pulisher
Jul 20, 2024

Artiva Biotherapeutics surges on trading debut - MSN

Jul 20, 2024
pulisher
Jul 19, 2024

Public Equity Report: Artiva’s debut comes amid underwhelming IPO season - BioCentury

Jul 19, 2024
pulisher
Jul 19, 2024

Artiva Biotherapeutics IPO opens at $16, priced at $12 By Investing.com - Investing.com Canada

Jul 19, 2024
pulisher
Jul 19, 2024

Artiva prices $167M IPO as its AlloNK cell therapy advances - BioWorld Online

Jul 19, 2024
pulisher
Jul 19, 2024

Artiva Shares Jump 30% After Upsized $167 Million US IPO - Bloomberg

Jul 19, 2024
pulisher
Jul 19, 2024

Artiva Biotherapeutics announces pricing of upsized $167M IPO - MSN

Jul 19, 2024
pulisher
Jul 19, 2024

Cooley, Latham Lead Biotech Firm Artiva's Upsized $167M IPO - Law360

Jul 19, 2024
pulisher
Jul 19, 2024

Artiva Biotherapeutics stock in trading debut (Pending:ARTV) - Seeking Alpha

Jul 19, 2024
pulisher
Jul 19, 2024

Watkins Advises on Artiva Biotherapeutics’ US$167.0 Million Initial Public Offering - Latham & Watkins LLP -

Jul 19, 2024
pulisher
Jul 19, 2024

Artiva Biotherapeutics Prices 13.92M Share IPO at $12/sh - Investing.com

Jul 19, 2024
pulisher
Jul 19, 2024

Artiva Biotherapeutics announces pricing of upsized $167M IPO (Pending:ARTV) - Seeking Alpha

Jul 19, 2024
$22.32
price down icon 1.11%
$74.12
price up icon 0.26%
$373.97
price up icon 3.48%
$54.36
price down icon 0.66%
$202.64
price down icon 1.63%
$113.10
price down icon 0.74%
Kapitalisierung:     |  Volumen (24h):